E1	Eq-Comparison:T1 Temporal-Period:T14
E2	Drug:T2 Name:T16
E3	Procedure:T3 Name:T24 Temporality:E1 Location:T26
E4	Eq-Comparison:T4 Operator:T17 Value:T18 Temporal-Unit:T19
E6	Eq-Comparison:T6 Temporal-Recency:T28
E7	Study:T7 Temporality:E6 Study-Of:E17
E8	Negation:T8 Negates:E19
E9	Eq-Comparison:T9 Temporal-Period:T20
E11	Eq-Comparison:T11 Operator:T21 Value:T22 Temporal-Unit:T23
E13	Study:T13 Study-Of:E18
E16	Procedure:T29 
E17	Procedure:T30 
E18	Procedure:T31 
E19	Study:T32 Temporality:E9 Study-Of:E16
T1	Eq-Comparison 25 34	Currently
T2	Drug 109 124	methamphetamine
T3	Procedure 125 142	treatment program
T4	Eq-Comparison 204 220	within two weeks
T6	Eq-Comparison 224 231	initial
T7	Study 232 242	enrollment
T8	Negation 300 303	Not
T9	Eq-Comparison 304 313	currently
T11	Eq-Comparison 366 385	more than two weeks
T13	Study 391 401	enrollment
T14	Eq-Temporal-Period 25 34	Currently
T16	Drug-Name 109 124	methamphetamine
T17	Eq-Operator 204 210	within
T18	Eq-Value 211 214	two
T19	Eq-Temporal-Unit 215 220	weeks
T20	Eq-Temporal-Period 304 313	currently
T21	Eq-Operator 366 375	more than
T22	Eq-Value 376 379	two
T23	Eq-Temporal-Unit 380 385	weeks
T24	Procedure-Name 125 142	treatment program
T26	Location 172 192	Los Angeles, CA, USA
T28	Eq-Temporal-Recency 224 231	initial
T29	Procedure 348 355	program
T30	Procedure 266 273	program
T31	Procedure 423 430	program
T32	Study 314 322	enrolled
A3	Eq-Temporal-Period-Value T14 present
A5	Eq-Operator-Value T17 LTEQ
A6	Eq-Temporal-Unit-Value T19 week
A7	Eq-Temporal-Period-Value T20 present
A8	Eq-Operator-Value T21 GT
A9	Eq-Temporal-Unit-Value T23 week
A10	Location-Value T26 residence
A11	Eq-Temporal-Recency-Value T28 first-time
R1	Using Arg1:E3 Arg2:E2
R3	Before Arg1:E4 Arg2:E6
R4	Or Arg1:E8 Arg2:E13
R5	After Arg1:E11 Arg2:E13
R6	And Arg1:E3 Arg2:E7
T5	Encounter 98 108	outpatient
E5	Encounter:T5 
A1	Encounter-Type-Value E5 outpatient
R7	During Arg1:E5 Arg2:E3	
